Asset Details
Do you wish to reserve the book?
Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis
Do you wish to request the book?
Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis
2019
Overview
Epithelial barrier loss is a driver of intestinal and systemic diseases. Myosin light chain kinase (MLCK) is a key effector of barrier dysfunction and a potential therapeutic target, but enzymatic inhibition has unacceptable toxicity. Here, we show that a unique domain within the MLCK splice variant MLCK1 directs perijunctional actomyosin ring (PAMR) recruitment. Using the domain structure and multiple screens, we identify a domain-binding small molecule (divertin) that blocks MLCK1 recruitment without inhibiting enzymatic function. Divertin blocks acute, tumor necrosis factor (TNF)-induced MLCK1 recruitment as well as downstream myosin light chain (MLC) phosphorylation, barrier loss, and diarrhea in vitro and in vivo. Divertin corrects barrier dysfunction and prevents disease development and progression in experimental inflammatory bowel disease. Beyond applications of divertin in gastrointestinal disease, this general approach to enzymatic inhibition by preventing access to specific subcellular sites provides a new paradigm for safely and precisely targeting individual properties of enzymes with multiple functions.
A small molecule that restores the integrity of the intestinal barrier provides a novel therapeutic strategy for inflammatory bowel diseases.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Chains
/ Diarrhea
/ Disease
/ Enzymes
/ Humans
/ Inflammatory Bowel Diseases - pathology
/ Intestinal Mucosa - drug effects
/ Intestinal Mucosa - metabolism
/ Intracellular Space - enzymology
/ Kinases
/ Mice
/ Mucosa
/ Myosin
/ Myosin Light Chains - metabolism
/ Myosin-Light-Chain Kinase - chemistry
/ Myosin-Light-Chain Kinase - metabolism
/ Necrosis
/ Novels
/ Phosphorylation - drug effects
/ Screens
/ Small Molecule Libraries - pharmacology
/ Tight Junctions - drug effects
/ Tight Junctions - metabolism
/ Toxicity
/ Tumor Necrosis Factor-alpha - pharmacology
/ Tumors
